6 papers in the library · 7 citations · publishing 2006-2026
European Psychiatry June 23, 2026 Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
The International Journal of Neuropsychopharmacology May 5, 2026 Hiroyuki Uchida, Gabriella Gobbi, Joseph Zohar et al.
BACKGROUND: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. METHODS: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence,...
Frontiers in Psychiatry 2026 C M Diendorfer, C Bum, A Weidenauer et al.
Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...
Wiener klinische Wochenschrift March 1, 2025 Pia Baldinger-Melich, Marie Spies, Ina Bozic et al. 5 citations
Modern electroconvulsive therapy (ECT) and the approval of nasal esketamine for clinical use have significantly improved the approach to treatment-resistant depression (TRD), which is defined as non-response to at least two different courses of antidepressants with verified adherence to treatment, adequate dosage, and duration of treatment. The goal of this literature review is to present the...
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry November 1, 2024 Samantha Graf, Gregor Dörl, Christian Milz et al. 2 citations
Ketamine exerts rapid antidepressant effects by enhancing neuroplasticity, particularly in the amygdala and hippocampus-regions involved in fear processing and learning. While the role of ketamine's dissociative effects in its antidepressant response is debated, anxiety experienced during infusion has been negatively correlated with treatment outcomes. In this single-blind, placebo-controlled...
Biological Psychiatry April 15, 2006 Dan Rujescu, Andreas Bender, Martin Keck et al.
The psychotomimetic effects of N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) in healthy humans and their ability to exacerbate psychotic symptoms in schizophrenic patients have promoted a view of schizophrenia as being related to altered glutamatergic neurotransmission. This prompted us and others to develop animal models for psychosis based on a glutamatergic...